Article

Nutrition a priority for dry eye patients

Author(s):

Julianne Mobilian
Conferences|ASCRS

Here's why John Sheppard, MD, believes nutrition should be the cornerstone of dry eye therapy.

John Sheppard, MD, discusses the benefits of supplementing nutraceuticals with other treatments to improve dry eye symptoms at the annual 2019 ASCRS meeting in San Diego. 

RELATED: Lid hygiene device improves meibomian gland dysfunction, blepharitis

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
Related Content
FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap
July 17th 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Precautionary recall announced for specific batch of Zaditen eye drops in the UK
July 8th 2025

Precautionary recall announced for specific batch of Zaditen eye drops in the UK

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Stuart Therapeutics releases initial results of phase 3 clinical trial evaluating ST-100 (vezocolmitide) ophthalmic solution for dry eye disease
June 26th 2025

Stuart Therapeutics releases initial results of phase 3 clinical trial evaluating ST-100 (vezocolmitide) ophthalmic solution for dry eye disease

New TFOS DEWS III Digest report highlights relevant research on management, treatment of DED
June 22nd 2025

New TFOS DEWS III Digest report highlights relevant research on management, treatment of DED

© 2025 MJH Life Sciences

All rights reserved.